L. Mouthon, A. Berezné, V. L. Guern, and L. Guillevin, Indications thérapeutiques des immunoglobulines intraveineuses, vol.1018, pp.1122-1184

C. Galeotti, M. S. Maddur, M. Kazatchkine, L. Mouthon, and S. Kaveri, Immunoglobulines intraveineuses dans les maladies auto-immunes et inflammatoires : au-delà d'une simple substitution, Transfus Clin Biol, vol.16, issue.2, pp.75-84, 2009.

A. Rütter and T. A. Luger, High-Dose Intravenous Immunoglobulins: An Approach to Treat Severe Immune-Mediated and Autoimmune Diseases of the Skin, J Am Acad Dermatol, vol.44, issue.6, pp.1010-1034, 2001.

V. Behring, E. Kitasato, and S. , The mechanism of diphtheria immunity and tetanus immunity in animals, Mol Immunol, vol.28, issue.12, pp.1319-1339, 1991.

O. C. Bruton, Agammaglobulinemia. Pediatrics, vol.9, issue.6, pp.722-730, 1952.

E. W. Gelfand, Intravenous Immune Globulin in Autoimmune and Inflammatory Diseases, N Engl J Med, vol.367, issue.21, pp.2015-2040, 2012.

Y. Chen, C. Wang, F. Xu, F. Ming, and H. Zhang, Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases, Clin Ther, vol.41, issue.10, pp.2112-2148, 2019.

I. Elovaara, S. Apostolski, P. Van-doorn, N. E. Gilhus, A. Hietaharju et al., EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases, Eur J Neurol, vol.15, issue.9, pp.893-908, 2008.

E. E. Perez, J. S. Orange, F. Bonilla, J. Chinen, I. K. Chinn et al., Update on the use of immunoglobulin in human disease: A review of evidence, J Allergy Clin Immunol, vol.139, issue.3S, pp.1-46, 2017.

I. N. Van-schaik, L. H. Van-den-berg, R. De-haan, and M. Vermeulen, Intravenous immunoglobulin for multifocal motor neuropathy, Cochrane Database Syst Rev, issue.2, p.4429, 2005.

T. Harbo, H. Andersen, A. Hess, K. Hansen, S. H. Sindrup et al., Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial, Eur J Neurol, vol.16, issue.5, pp.631-639, 2009.

P. Van-den-bergh, R. Hadden, P. Bouche, D. R. Cornblath, A. Hahn et al., European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society -first revision, Eur J Neurol, vol.17, issue.3, pp.356-63, 2010.

K. Viala, Les neuropathies dysimmunes : la place du syndrome de Lewis et Sumner. Mise au point, vol.6, 2003.

, Portail des maladies rares et médicaments orphelins. Myasthénie acquise, Orphanet, p.82, 2009.

N. Melzer, T. Ruck, P. Fuhr, R. Gold, R. Hohlfeld et al., Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society, J Neurol, vol.263, issue.8, pp.1473-94, 2016.

G. O. Skeie, S. Apostolski, A. Evoli, N. E. Gilhus, I. I. Harms et al., Guidelines for treatment of autoimmune neuromuscular transmission disorders, Eur J Neurol, vol.17, issue.7, pp.893-902, 2010.

P. Gajdos, S. Chevret, C. B. Tranchant, C. Chastang, and C. , Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis, Myasthenia Gravis Clinical Study Group. Ann Neurol, vol.41, issue.6, pp.789-96, 1997.

P. Gajdos, C. Tranchant, C. B. Bolgert, F. Eymard, B. Stojkovic et al., Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin: A Randomized Double-blind Clinical Trial, Arch Neurol, vol.62, issue.11, pp.1689-93, 2005.

G. Guillain, J. A. Barré, and A. Strohl, Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes, 1916.

, Ann Med Interne (Paris), vol.150, issue.1, pp.24-32, 1999.

E. E. Perez, J. S. Orange, F. Bonilla, J. Chinen, I. K. Chinn et al., Update on the use of immunoglobulin in human disease: A review of evidence, J Allergy Clin Immunol, vol.139, issue.3S, pp.1-46, 2017.

. Oms and . Syndrome-de-guillain-barré, , 2016.

. Hughes-r-a.-c, E. Wijdicks, R. Barohn, E. Benson, D. R. Cornblath et al., Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology, vol.61, issue.6, pp.736-776, 2003.

R. Hughes, A. V. Swan, J. Raphaël, D. Annane, R. Van-koningsveld et al., Immunotherapy for Guillain-Barré syndrome: a systematic review, Brain J Neurol, vol.130, pp.2245-57, 2007.

F. G. Van-der-meché and P. I. Schmitz, A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group, N Engl J Med, vol.326, issue.17, pp.1123-1132, 1992.

P. Guilpain, Y. Chanseaud, M. C. Tamby, C. Larroche, L. Guillevin et al., Effets immunomodulateurs des immunoglobulines intraveineuses. Presse Médicale, vol.33, pp.1183-94, 2004.

L. Mouthon, G. Bussone, and S. Kaveri, Indications et mécanismes d'action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques. Rev Médecine Interne, vol.30, pp.14-20, 2009.

P. Imbach, S. Barandun, V. Apuzzo, C. Baumgartner, A. Hirt et al., High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood, Lancet Lond Engl, vol.1, issue.8232, pp.1228-1259, 1981.

W. Sewell, J. Kerr, M. Behr-gross, H. Peter, and K. Group, European consensus proposal for immunoglobulin therapies, Eur J Immunol, vol.44, issue.8, pp.2207-2221, 2014.

J. Kerr, I. Quinti, M. Eibl, H. Chapel, P. J. Späth et al., Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe, Front Immunol, vol.5, p.629, 2014.

F. Gay-crosier, U. Nydegger, and J. Villard, Peut-on se passer des immunoglobulines polyclonales intraveineuses (IVIg) ?, Revue Médicale Suisse, 2020.

O. Veran, La filière du sang en France, 2019.

J. Bayry, M. D. Kazatchkine, and S. V. Kaveri, Shortage of human intravenous immunoglobulin--reasons and possible solutions, Nat Clin Pract Neurol, vol.3, issue.3, pp.120-121, 2007.

I. Elovaara, S. Apostolski, P. Van-doorn, N. E. Gilhus, A. Hietaharju et al., EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases, Eur J Neurol, vol.15, issue.9, pp.893-908, 2008.

J. M. Phuong, J. Penm, B. Chaar, L. D. Oldfield, and R. Moles, The impacts of medication shortages on patient outcomes: A scoping review, PLoS One, vol.14, issue.5, p.215837, 2019.

E. E. Perez, J. S. Orange, F. Bonilla, J. Chinen, I. K. Chinn et al., Update on the use of immunoglobulin in human disease: A review of evidence, J Allergy Clin Immunol, vol.139, issue.3S, pp.1-46, 2017.

F. Eftimov, J. B. Winer, M. Vermeulen, R. De-haan, and . Van-schaik, Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, p.1797, 2009.

P. Gajdos, C. Tranchant, C. B. Bolgert, F. Eymard, B. Stojkovic et al., Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin: A Randomized Double-blind Clinical Trial, Arch Neurol, vol.62, issue.11, pp.1689-93, 2005.

K. Kuitwaard, P. A. Van-doorn, M. Vermeulen, L. H. Van-den-berg, E. Brusse et al., Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy, J Neurol Neurosurg Psychiatry, vol.84, issue.8, pp.859-61, 2013.

Y. A. Rajabally, S. L. Wong, and D. A. Kearney, Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens?, J Neurol, vol.260, issue.8, pp.2052-2058, 2013.

R. Hughes, S. Bensa, H. Willison, P. Van-den-bergh, G. Comi et al., Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy, Ann Neurol, vol.50, issue.2, pp.195-201, 2001.

E. Nobile-orazio, D. Cocito, J. S. Uncini, A. Beghi, E. Messina et al., Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial, Lancet Neurol, vol.11, issue.6, pp.493-502, 2012.

N. Latov, C. Deng, M. C. Dalakas, V. Bril, P. Donofrio et al., Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy, Arch Neurol, vol.67, issue.7, pp.802-809, 2010.

R. Hughes, P. Donofrio, V. Bril, M. C. Dalakas, C. Deng et al., Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial, Lancet Neurol, vol.7, issue.2, pp.136-180, 2008.

I. N. Van-schaik, F. Eftimov, P. A. Van-doorn, E. Brusse, L. H. Van-den-berg et al., Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial, Lancet Neurol, vol.9, issue.3, pp.245-53, 2010.

P. J. Dyck, W. J. Litchy, K. M. Kratz, G. A. Suarez, P. A. Low et al., A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy, Ann Neurol, vol.36, issue.6, pp.838-883, 1994.

R. A. Hughes, M. M. Mehndiratta, Y. A. Rajabally, F. Eftimov, M. H. Liesdek et al., Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev, BMC Neurol, vol.11, issue.11, p.72, 2014.

J. Franques, J. Azulay, J. Pouget, and S. Attarian, Les polyradiculonévrites inflammatoires démyélinisantes chroniques. Rev Médecine Interne, vol.31, pp.411-417, 2010.

S. Attarian, A. Verschueren, J. Franques, E. Salort-campana, E. Jouve et al., Response to treatment in patients with Lewis-Sumner syndrome, Muscle Nerve, vol.44, issue.2, pp.179-84, 2011.

A. Pestronk, D. R. Cornblath, A. A. Ilyas, H. Baba, R. H. Quarles et al., A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside, Ann Neurol, vol.24, issue.1, pp.73-81, 1988.

L. Vlam, W. Van-der-pol, E. A. Cats, D. C. Straver, S. Piepers et al., Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies, Nat Rev Neurol, vol.8, issue.1, pp.48-58, 2011.

M. Jinka and V. Chaudhry, Treatment of multifocal motor neuropathy, Curr Treat Options Neurol

, Feb, vol.16, issue.2, p.269

T. Umapathi, R. A. Hughes, E. Nobile-orazio, and J. M. Léger, Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy. Cochrane Database Syst Rev, vol.2015, p.3217, 2015.

R. Hughes, A. V. Swan, and P. A. Van-doorn, Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev, p.2063, 2012.

R. A. Hughes, R. Brassington, A. A. Gunn, and P. A. Van-doorn, Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev, vol.10, p.1446, 2016.

C. Combe, L. Grattier-dondelinger, A. Guillermet, S. Bourget, J. Tomas et al., Coût du traitement par échanges plasmatiques vs immunoglobulines intraveineuses en réanimation, J Pharm Clin, vol.38, issue.2, pp.63-70, 2019.

I. Cortese, V. Chaudhry, Y. T. So, F. Cantor, and D. R. Cornblath, Rae-Grant A. Evidence-based guideline update, Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, 2011.

, une des 23 Filières de Santé Maladies Rares, a participé à l'élaboration du tableau de hiérarchisation des indications proposé par l'ANSM dans le but de promouvoir l'épargne des Ig. Selon ce tableau, la seule situation AMM qui justifie une administration d'Ig IV en neurologie est le SGB chez l'enfant et l'adulte en cas de contre-indication ou d

, Myasthénie ou syndrome de Lambert-Eaton 9 . FILNEMUS a souhaité évaluer l'impact de ces recommandations de hiérarchisation en, Ig IV dans les autres indications ne sont à réserver qu'en cas d'urgences vitales : NMM, PIDC, 2018.

W. Sewell, J. Kerr, M. E. Behr-gross, and H. H. Peter, European consensus proposal for immunoglobulin therapies, Eur J Immunol, vol.44, issue.8, pp.2207-2221, 2014.

, Document relatif àl'utilisation des immunoglobulines humaines polyvalentes (Ig) dans un contexte de tensions d'approvisionnement, ANSM, 2019.

, ANSM. Sécurisation de l'accès aux médicaments dérivés du sang pour les patients dans un contexte de difficultés d'approvisionnement, 2018.

S. Attarian and A. D. , enquête FILNEMUS sur l'utilisation des IgIV en 2018

, En effet les tensions d'approvisionnement pourraient s'accentuer au cours des prochains mois, en raison en partie d'une pénurie de la collecte de sang et de plasma. Une stratégie globale de prescription est donc indispensable, En outre, l'intérêt de ces réévaluations est toujours présent compte tenu de la fragilité du marché des maladies post COVID 19

N. Rezaei, H. Abolhassani, A. Aghamohammadi, and H. D. Ochs, Indications and safety of intravenous and subcutaneous immunoglobulin therapy, Expert Review of Clinical Immunology, vol.7, issue.3, pp.301-317, 2011.